Art

J-GLOBAL ID：201902282578146365   Reference number：19A2498892

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

視神経脊髄炎スペクトラム障害(N-運動量)の治療のためのネビリズマブ:二重盲検無作為化プラセボ対照第2相試験【JST・京大機械翻訳】

Author (24)： Cree Bruce A C (UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA) ,  Bennett Jeffrey L (School of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA) ,  Kim Ho Jin (Research Institute and Hospital of National Cancer Center, Seoul, South Korea) ,  Weinshenker Brian G (Mayo Clinic, Rochester, MN, USA) ,  Pittock Sean J (Mayo Clinic, Rochester, MN, USA) ,  Wingerchuk Dean M (Mayo Clinic, Scottsdale, AZ, USA) ,  Fujihara Kazuo (Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima, Japan) ,  Fujihara Kazuo (Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Koriyama, Japan) ,  Paul Friedemann (Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany) ,  Paul Friedemann (Charite-Universitaetsmedizin Berlin, Berlin, Germany) ,  Cutter Gary R (Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA) ,  Marignier Romain (Service de Neurologie, Sclerose en Plaques, Pathologies de la Myeline et Neuro-inflammation, Lyon University Hospital, Lyon, France) ,  Green Ari J (UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA) ,  Green Ari J (Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA) ,  Aktas Orhan (Medical Faculty, Heinrich Heine University, Duesseldorf, Germany) ,  Hartung Hans-Peter (Medical Faculty, Heinrich Heine University, Duesseldorf, Germany) ,  Lublin Fred D (Icahn School of Medicine at Mount Sinai, New York, NY, USA) ,  Drappa Jorn (Viela Bio, Gaithersburg, MD, USA) ,  Barron Gerard (MedImmune, Cambridge, UK) ,  Madani Soraya (Viela Bio, Gaithersburg, MD, USA) ,  Ratchford John N (Viela Bio, Gaithersburg, MD, USA) ,  She Dewei (Viela Bio, Gaithersburg, MD, USA) ,  Cimbora Daniel (Viela Bio, Gaithersburg, MD, USA) ,  Katz Eliezer (Viela Bio, Gaithersburg, MD, USA)
Material： Lancet
Volume： 394  Issue： 10206  Page： 1352-1363  Publication year： 2019 
JST Material Number： B0673A  ISSN： 0140-6736  CODEN： LANCA  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： No approved therapies exist fo...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A2498892&from=J-GLOBAL&jstjournalNo=B0673A") }}

Thesaurus term： antibody ,  human ,  *placebo ,  *double blind test ,  Recurrence ,  therapy ,  effectiveness ,  Safety ,  seizure (disease) ,  Web (information system) ,  screening (inspection) ,  adult (person) ,  vein ,  end point ,  adverse reaction
Semi thesaurus term： 有害事象 ,  スコア , 【Automatic Indexing@JST】

JST classification (3)： Metabolic diseases,nutritional diseases in general.  (GD05010J) ,  Drug therapy(=pharmacotherapy)for nervous system diseases  (GN05020Y) ,  Treatment for nervous system diseases in general  (GN05010N)

Terms in the title (7)： 視神経脊髄炎スペクトラム障害 ,  運動量 ,  治療 ,  二重盲検 ,  プラセボ ,  対照 ,  第2相試験